Kumagai et al. hypothesized that the frequency of PD-1 + CD8 + lymphocytes in relation to the frequency of PD-1 + regulatory T lymphocytes in the tumor microenvironment can predict the clinical efficacy of immunotherapies and is superior to PD-L1 tumor cell expression as indicator of treatment response [11]. The gene discussed is PDCD1; the disease is neoplasm.